Vivani Medical (VANI) Emerging Growth Virtual Conference 78 summary

Program updates and clinical progress

• Developing a six-month GLP-1 implant for chronic weight management and diabetes, aiming to improve adherence and tolerability.

• LIBERATE-1, the first-in-human trial, was initiated late last year, with the first subjects entering the run-in phase this month.

• The study includes an eight-week run-in with semaglutide injections, followed by implant or comparator treatments to assess weight, pharmacokinetics, and tolerability.

• Results from the LIBERATE-1 study are expected around mid-year, with plans to use findings to design future studies for both weight management and Type 2 diabetes.

• A dose-finding study and a potential registrational trial are planned, with a semaglutide implant and animal health applications also in the pipeline.

Technology and platform strategy

• NanoPortal platform uses titanium oxide nanotubes to control drug release rates and is licensable for other products.

• The LIBERATE-1 study is the first human trial of the NanoPortal technology, aiming to demonstrate its platform potential.

• Broader application of NanoPortal is planned across chronic diseases, with partnership discussions anticipated.

Market focus and future outlook

• Initial target market is individuals who have lost weight on GLP-1 therapy and seek long-term maintenance without frequent dosing.

• Market research suggests a segment of patients, similar to those choosing IUDs or implants for contraception, may prefer this approach.

• 2025 is anticipated to be a transformational year, with a robust pipeline and further updates expected.